We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,203

The Demise of Valeant Pharmaceuticals: A Case Study in Rotten Culture and Business Ethics
  • Volkov Law Group
  • USA
  • April 3 2016

Showing my age again, Woody Allen’s Take the Money and Run included a hilarious scene when Woody’s parents wearing Groucho Marx glasses talk about


Drug and Medical Device Corruption Risks in China
  • Volkov Law Group
  • China, USA
  • March 7 2016

Medical device and pharmaceutical companies know the risks of conducting business in China. Company after company has had to settle FCPA enforcement


eCommerce Regulation, Bitcoin, Anti-Money Laundering, Shadow Insurance, 401(k) Litigation Expect Focus - Vol. IV, Fall 2015
  • Carlton Fields
  • USA
  • December 23 2015

On January 1, 2016, Section 38.6 of the California Insurance Code will take effect permitting consumers to conduct certain life, disability, and


Corporate Crime & Investigations Update - 11 January 2016
  • Addleshaw Goddard LLP
  • Ukraine, United Kingdom, USA
  • January 11 2016

Southwark Crown Court ordered Smith and Ouzman Ltd. to pay a total of approximately £2.2 million in relation to bribes paid to public officials for


FDA to increase enforcement actions against corporate officials
  • Faegre Baker Daniels LLP
  • USA
  • March 5 2010

Corporate executives have rarely been personal targets of FDA enforcement actions


Employee charged with theft of company trade secrets
  • Epstein Becker Green
  • USA
  • February 9 2010

The importance of corporate security and vigilance with regard to trade secrets was demonstrated by recent events in Syracuse, New York


Ten steps global life sciences companies should take in 2011
  • Sidley Austin LLP
  • USA
  • February 16 2011

Focus on potential kickback, Foreign Corrupt Practices Act, and Good Clinical Practice liability, especially in developing countries


Responding to a government subpoena or other document demand - six helpful hints
  • Ober Kaler
  • USA
  • December 31 2013

Presented by Gina L. Simms and James P. Holloway of OberKaler's Government Investigations and White Collar Defense Group, this podcast provides


How to respond to a search warrant - ten practical steps
  • Ober Kaler
  • USA
  • December 31 2013

Presented by Gina L. Simms and James P. Holloway of OberKaler's Government Investigations and White Collar Defense Group, this podcast provides


OIG Advisory Opinion 12-05 approves consumer rewards program
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • May 2 2012

In OIG Advisory Opinion 12-05, the OIG found that a consumer rewards program (the “Program”) offered by a supermarket chain with in-store and independent pharmacies (the “Requestor”) would not be subject to enforcement under the Anti-Kickback Statute (the “Kickback Statute”) or the beneficiary inducement prohibition found in the civil monetary penalties law (the “CMP Law”